Key result
Targeted cardioprotective agents may mitigate doxorubicin-induced cardiac mitochondrial bioenergetic collapse.
Why the study?
Doxorubicin-induced cardiovascular disease is a primary cause of mortality in cancer survivors, with cardiac mitochondrial bioenergetics changes serving as a significant marker.
Do chemical drugs and traditional herbal medicine interventions targeting mitochondrial bioenergetics prevent or ameliorate doxorubicin-induced cardiotoxicity?
Do chemical drugs and traditional herbal medicine interventions targeting mitochondrial bioenergetics prevent or ameliorate doxorubicin-induced cardiotoxicity?
This narrative review synthesizes the molecular mechanisms of doxorubicin-induced mitochondrial bioenergetic collapse and highlights potential chemical and herbal therapeutic targets to prevent anthracycline cardiotoxicity.
Answers are grounded in this paper and cite their sources.
No immediate change to anthracycline protocols warranted; leaves open whether mitochondrial-targeted chemical or herbal agents improve outcomes.
Doxorubicin (DOX) is an anthracycline chemotherapy drug, which is indispensable in antitumor therapy. However, its subsequent induction of cardiovascular disease (CVD) has become the primary cause of mortality in cancer survivors. Accumulating evidence has demonstrated that cardiac mitochondrial bioenergetics changes have become a significant marker for doxorubicin-induced cardiotoxicity (DIC). Here, we mainly summarize the related mechanisms of DOX-induced cardiac mitochondrial bioenergetics disorders reported in recent years, including mitochondrial substrate metabolism, the mitochondrial respiratory chain, myocardial ATP storage and utilization, and other mechanisms affecting mitochondrial bioenergetics. In addition, intervention for DOX-induced cardiac mitochondrial bioenergetics disorders using chemical drugs and traditional herbal medicine is also summarized, which will provide a comprehensive process to study and develop more appropriate therapeutic strategies for DIC.
No takes yet. Share an insight, caveat, or question.
Ling et al. (2022) conducted a review in Doxorubicin-induced cardiotoxicity (DIC). Chemical drugs (e.g., dexrazoxane, metformin, carvedilol, statins, LCZ696, empagliflozin) and traditional herbal medicine compounds was evaluated on Prevention and alleviation of doxorubicin-induced cardiac mitochondrial bioenergetics disorders and cardiotoxicity. Doxorubicin impairs cardiac mitochondrial bioenergetics across substrate metabolism, respiratory chain, and ATP storage, which targeted chemical and herbal interventions may help mitigate.
Synapse has enriched 10 related papers. Consider them for comparative context: